Somewhat Positive News Coverage Somewhat Unlikely to Impact Amphastar Pharmaceuticals (AMPH) Stock Price

Media headlines about Amphastar Pharmaceuticals (NASDAQ:AMPH) have trended somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.9134845596457 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:

Amphastar Pharmaceuticals (AMPH) traded up 3.33% during mid-day trading on Friday, hitting $15.22. 271,628 shares of the company traded hands. The company’s 50-day moving average price is $16.86 and its 200 day moving average price is $15.89. The company has a market capitalization of $703.09 million, a price-to-earnings ratio of 197.66 and a beta of 1.65. Amphastar Pharmaceuticals has a one year low of $12.05 and a one year high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, August 9th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The business had revenue of $65.20 million during the quarter, compared to analysts’ expectations of $63.40 million. During the same period in the prior year, the business earned $0.23 EPS. Amphastar Pharmaceuticals’s revenue for the quarter was down 4.1% compared to the same quarter last year. On average, analysts anticipate that Amphastar Pharmaceuticals will post $0.27 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals announced that its board has initiated a share repurchase program on Wednesday, August 9th that allows the company to buyback $20.00 million in shares. This buyback authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Several research analysts have commented on the stock. Piper Jaffray Companies set a $20.00 target price on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, July 29th. BidaskClub cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. BMO Capital Markets reiterated a “hold” rating and issued a $16.00 target price on shares of Amphastar Pharmaceuticals in a report on Monday, July 31st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $19.00 target price (down from $20.00) on shares of Amphastar Pharmaceuticals in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $19.86.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Amphastar Pharmaceuticals (AMPH) Stock Price” was originally published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/amphastar-pharmaceuticals-amph-earns-news-sentiment-rating-of-0-18-updated-updated.html.

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $14.81, for a total transaction of $148,100.00. Following the completion of the transaction, the director now owns 33,844 shares of the company’s stock, valued at approximately $501,229.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard K. Prins sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $14.80, for a total value of $74,000.00. Following the transaction, the director now directly owns 33,844 shares of the company’s stock, valued at approximately $500,891.20. The disclosure for this sale can be found here. Over the last three months, insiders have sold 51,482 shares of company stock valued at $842,225. 11.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply